anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
Systems and methods are provided herein for treating a patient in cardiogenic shock. An intravascular heart pump system is inserted into vasculature of the patient. The heart pump system has a cannula, pump outlet, pump inlet, and rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient's aortic valve, the pump inlet is located within the patient's left ventricle, and the pump outlet is located within the patient's aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. A plurality of features are extracted from the data. A probability of survival of the patient is determined based on the plurality of features and using a prediction model. The heart pump system is operated to treat the patient.
A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R 2  represents NHSO 2 R 3 , etc., provided that R 3  represents C 1-6  alkyl, etc. R 5  represents hydrogen, etc. R 6  and R 7  may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z 1  to Z 6  each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R 5  is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.
PURPOSE:To obtain a diagnostic agent for cancer generating a tumor marker having cancerous fucosylated sugar chain by using an immobilized AAL lectin as an active component. CONSTITUTION:Body fluid collected from a patient is passed through a column containing AAL lectin immobilized by using sepharose beads, agarose beads, cellulose beads, polyacrylamide beads, etc., as a carrier. The immobilized lectin is washed with a buffer liquid such as PBS to collect a washing fraction and then treated with a fucose-containing buffer liquid to collect an eluted fraction. The tumor markers existing in the washing fraction and the eluted fraction are determined and compared. The patient is judged to be affected by cancer when the marker is abundant in the eluted fraction compared with the washing fraction. The tumor markers eluted into the eluted fraction can be recovered with an immobilized AAL lectin. The process can be applied to various tumor markers such as CA19-9 for pancreatic cancer, CEA for digestive tract cancer, DU-PAN-2 for pancreatic cancer, sialyl Lewis x-i for pulmonary adenocarcinoma, etc., Le<b> for adenocarcinoma and CA125 for ovarian cancer.
This will be a single-center, open-label, randomized prospective study. Primary outcome will be percent of time within a specific INR range. Subjects will be randomized to to control and treatment groups and stratified 1:1 based on sex. The control group will have warfarin doses adjusted by experts in the treatment of patients with warfarin. The treatment group will have warfarin doses determined using a clinical support tool based on reinforcement learning. Based on simulations of the experimental design with an expectation that the percent of INR values within the target range increase by 20%, 70 subjects per group are required for statistical significance. Based on an attrition rate of 15%, the investigators will enroll 80 subjects per group. Statistical analysis will compare the percent of patients within the target INR range between groups as the primary outcome with number of adverse events between groups as the safetly outcome.
Isolated LY6K-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can be promiscuously bind to MHC class II molecules and induce LY6K-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, esophageal cancer, gastric cancer, non-small cell lung cancer (NSCLC), osteosarcoma, pancreatic cancer, soft tissue tumor and head-and-neck malignant tumor (HNMT).
The invention discloses a Chinese traditional medicine composition for treating cholelithiasis and a method for preparing the same, which belong to the technical field of Chinese traditional medicines. The Chinese traditional medicine composition mainly comprises the following components in portion by weight: 30 portions of loosestrife, 15 portions of climbing fern, 10 portions of fructus toosendan, 10 portions of chickens gizzard-membrane, 10 portions of herba artemisiae, 10 portions of Chuan radix curcumae, 10 portions of corktree bark, 10 portions of elecampane, 10 portions of fruit of immature citron, 10 portions of rhubarb, and 10 portions of radix bupleuri. The components of the Chinese traditional medicine composition can be increased or decreased according to a principle of diagnosis and treatment on the basis of the basic components. The Chinese traditional medicine composition can be decocted with water or can be made into a mixture for taking. The Chinese traditional medicine composition has the advantages of low price, simple and convenient operation, and convenience for taking without toxic side effects. The Chinese traditional medicine composition can be prepared by a patient, has the curative ratio of cholelithiasis caused by various reasons being 96 percent, and has the total efficiency being 98.5 percent without relapse. Compared with other drugs at present, the Chinese traditional medicine composition has extremely remarkable effect.
BACKGOUND: The number of endovascular abdominal aortic aneurysm repairs (EVARs) has surpassed the number of open surgical repair of AAAs worldwide with a great variety of endografts being available. The aim of this study is to conduct a systematic review of the literature and meta-analysis of studies reporting patients with infrarenal abdominal aortic aneurysm (AAA) subjected to EVAR with the Anaconda endograft.
METHODS: We performed a systematic review of multiple electronic databases for studies including patients with infrarenal AAA who were subjected to elective EVAR with Anaconda endograft exclusively. We conducted a proportional meta-analysis cumulating the results of the included studies. The endpoints were first month overall mortality, first and second-year survival after EVAR, AAA-related deaths, incidence of endoleaks, endograft migration, endograft occlusion, open conversion, and primary and secondary technical success. The mean value for each separate studied factor was calculated, and the respective percentage or incidence was extracted so that it can be compared to endograft outcome studies in the literature. We assessed the methodologic quality of studies by using the Briggs Institute critical appraisal tool.
RESULTS: Seven observational studies were found including 954 patients (males 91.9%, mean age 73.38 ± 6.97 years). The mean transverse diameter of AAAs was 56.83 ± 9.97 mm. The mean proximal aortic neck diameter and length were 23.06 ± 3.33 mm and 24.14 ± 12.16 mm, respectively. Increased aortic neck calcification and aortic neck thrombus were present in 12.5% of patients. The 30-day overall mortality post-EVAR was 1.3%, 1 and 2-year survival rates were 95.9% and 91.4%, respectively. The mean follow-up period in the studies was 46.59 ± 15.5 months. AAA-related mortality was 1.3%. Primary technical success was 97.9% and secondary success was 99.3%. Open conversion was required in 3.4% of all patients (0.6% during the primary operation [Prim. Op]). The most common endoleak was type II, reported in 17.4% of all patients. Early type Ia endoleak was reported in 1.5% of patients and late type Ia in 1.7%. Overall, 2 endoleaks type III and 1 type IV were reported. Endograft migration occurred in 1.7% of patients. Main body and/or one/both iliac legs thrombotic occlusion was found totally in 7.6% of patients (5 main body occlusions and 64 iliac leg occlusions).
CONCLUSIONS: The use of Anaconda endograft in electively treated patients with infrarenal AAAs presented good results with high technical success and low postoperative and mid-term complications, except for an increased incidence of stent-graft thrombosis, which seems to be the "Achilles heel" of the device.
The invention relates to medicine, in particular to ophthalmic transplantology, and can be used for surgically treating corneal diseases. The method involves applying a biocoating and subsequently securing said coating in the conjunctival cavity. The biocoating is in the form of a collagen base containing cultured porcine limbal growth cells. Said biocoating is secured to the episclera in the fornix area under the conjunctiva with the aid of an amniotic membrane. Tests show that the biocoating begins to be absorbed within a period of 10 to 14 days, which is two times more rapid than with the prototype. No side effects have been observed during the postoperative period. Complete corneal epithelialization and improved visual acuity have been noted in all patients.
AIM: The aim was to examine the quality of online patient information resources for patients considering parastomal hernia treatment.
METHODS: A Google search was conducted using lay search terms for patient facing sources on parastomal hernia. The quality of the content was assessed using the validated DISCERN instrument. Readability of written content was established using the Flesch-Kincaid score. Sources were also assessed against the essential content and process standards from the National Institute for Health and Care Excellence (NICE) framework for shared decision making support tools. Content analysis was also undertaken to explore what the sources covered and to identify any commonalities across the content.
RESULTS: Fourteen sources were identified and assessed using the identified tools. The mean Flesch-Kincaid reading ease score was 43.61, suggesting that the information was difficult to read. The overall quality of the identified sources was low based on the pooled analysis of the DISCERN and Flesch-Kincaid scores, and when assessed against the criteria in the NICE standards framework for shared decision making tools. Content analysis identified eight categories encompassing 59 codes, which highlighted considerable variation between sources.
CONCLUSIONS: The current information available to patients considering parastomal hernia treatment is of low quality and often does not contain enough information on treatment options for patients to be able to make an informed decision about the best treatment for them. There is a need for high-quality information, ideally co-produced with patients, to provide patients with the necessary information to allow them to make informed decisions about their treatment options when faced with a symptomatic parastomal hernia.
Hemophagocytic lymphohistiocytosis (HLH) has occurred in pediatric and adult patients taking SUBVENITE for various indications. HLH is a life-threatening syndrome of pathologic immune activation characterized by clinical signs and symptoms of extreme systemic inflammation. It is associated with high mortality rates if not recognized early and treated. Common findings include fever, hepatosplenomegaly, rash, lymphadenopathy, neurologic symptoms, cytopenias, high serum ferritin, hypertriglyceridemia, and liver function and coagulation abnormalities. In cases of HLH reported with SUBVENITE, patients have presented with signs of systemic inflammation (fever, rash, hepatosplenomegaly, and organ system dysfunction) and blood dyscrasias. Symptoms have been reported to occur within 8 to 24 days following the initiation of treatment. Patients who develop early manifestations of pathologic immune activation should be evaluated immediately, and a diagnosis of HLH should be considered. SUBVENITE should be discontinued if an alternative etiology for the signs or symptoms cannot be established.
The present study will test the implementation and sustainability of (a) a Computer-Assisted Cognitive-Behavioral Treatment (CACBT) for youth anxiety and (b) the BASC-2 TRS to identify anxious youth in the school setting using a cohort-sequential design (i.e., three years at 20 schools over the span of five years). There are 3 phases: Phase I (baseline): Gather data on prevalence and services provided via screening measures and treatment trackers: Phase II (implementation): Train school staff in the identification of anxious youth (i.e. BASC-2 TRS) and the provision of the intervention (i.e., CACBT), modifying assessment and treatment procedures so as to best fit each individual school. Identify barriers and facilitators of implementation by gathering the qualitative experience of school staff: Phase II (sustainability): Discontinue training and supervision. Assess sustainability of the assessment and intervention. Identify barriers and facilitators of implementation by gathering the qualitative experience of school staff.

'Camp Cope-A-Lot (Computer-assisted CBT program)"
Patients with melanoma of the extremities included in the protocol. SLNB will be performed with the addition of magtrace (SPIO) injection, 0.2 ml around previous scar. The patients will undergo MRI of the involved basin (Axilla-groin)and receive the SpIO injection the day before SLN biopsy. A separate SPIO MRI will be performed before the operation. All patients will receive all 3 methods for SLN identification as described in the protocol.
Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
<P>PROBLEM TO BE SOLVED: To provide a new means for stabilizing a structure formed by a component contributing to the formation of the structure of the preparation.  <P>SOLUTION: The skin care preparation comprises lysylglutamic acid and/or its salt. The preparation further comprises an ionizable component contributing to the formation of the structure of the preparation. The ionizable component contributing to the formation of the structure of the preparation is preferably selected from fatty acid soap, anionic surfactant, amphoteric surfactant, cationic surfactant, carboxyvinyl polymer which may be modified with an alkyl group, alginic acid, carboxymethyl cellulose, and clay mineral which may be modified with an organic compound. The content of the lysylglutamic acid and its salt is preferably ≥10 μM.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Informal caregivers play a significant role in providing care for older, often vulnerable, patients, and supporting them as they live with chronic diseases. Due to the rising prevalence of older vascular patients and their use of healthcare, the role of their informal caregivers will become more important. However, little is known about the experiences of informal caregivers of patients with critical limb-threatening ischemia and the impact of informal care on different aspects of these caregivers' lives. In addition, literature does not describe the burden this role brings with it, or lack thereof. Therefore a qualitative study using a phenomenological approach, specifically interpretive phenomenological analysis, was used to gain insight into the experiences of the primary informal caregivers of patients with chronic limb-threatening ischemia. Data were collected via semi-structured interviews and focus groups discussions. Fifteen primary informal caregivers of patients with critical limb-threatening ischemia under the care of the vascular surgeon at a tertiary teaching hospital in the Netherlands were included. Data analysis yielded three themes: the perceived identity of this group of caregivers; the varying intensity of informal care; and the collaboration between informal carers, their care recipients and the professional care provider within the vascular surgery department. In contrast to carers of other chronic diseases, the shifting intensity of care that informal caregivers of critical limb-threatening ischemia patients experience seems to prevent long-term overload. Adapting to that fluctuating situation requires flexibility from healthcare providers within the vascular surgery department. In addition, professionals need to involve informal caregivers in the patient's decision-making process and recognize their role in that process.
Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
Breast cancer (BrCa) is the most prevalent malignant tumor in women and one of the leading causes of female mortality. Its occurrence and progression are influenced by various factors, including genetics, environment, lifestyle, and hormones. In recent years, the gut microbiota has been identified as a significant factor affecting BrCa. The gut microbiota refers to the collective population of various microorganisms in the human gastrointestinal tract. Gut microbiota is closely associated with human health and disease development, participating in crucial physiological functions such as digestion, metabolism, immune response, and neural regulation. It has been found to influence the occurrence and treatment of BrCa through a variety of mechanisms. This article aims to review the immunomodulatory role of the gut microbiota in the development and treatment of BrCa.
###  Adults

The recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool until diarrhea is controlled, after which the dosage of loperamide hydrochloride capsules should be reduced to meet individual requirements. When the optimal daily dosage has been established, this amount may then be administered as a single dose or in divided doses.

The average daily maintenance dosage in clinical trials was 4 mg to 8 mg (two to four capsules per day). The maximum daily dosage is 16 mg (eight capsules per day). If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration. Loperamide hydrochloride capsules administration may be continued if diarrhea cannot be adequately controlled with diet or specific treatment.

###  Elderly

No formal pharmacokinetic studies were conducted in elderly subjects. However, there were no major differences reported in the drug disposition in elderly patients with diarrhea relative to young patients. No dose adjustment is required for the elderly.

In general, elderly patients may be more susceptible to drug-associated effects of the QT interval. Avoid loperamide hydrochloride capsules in elderly patients taking drugs that can result in prolongation of the QT interval (for example, Class IA or III antiarrhythmics) or in patients with risk factors for Torsades de Pointes (see WARNINGS).
The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to a composition comprising probiotics consisting of Lactobacillus rhamnosus LC70 alone or Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC705.Also the invention relates to the com- position for use as a medicament. Furthermore, the present invention relates to uses of Lactobacillus rhamnosus LC705 alone or together with Lactobacillus rhamnosus GG for the manufacture of a composition for the treatment and/or prevention of a respiratory infection and for intensifying resistance against viruses causing respiratory infections in a subject. Furthermore, the present invention describes uses of Lactobacillus rhamnosus GG for the manufacture of a composition for the treatment and/or prevention of a respiratory infection in an adult and for intensifying resistance against viruses causing respiratory infections in an adult subject. Still, the present invention relates to uses of Lactobacillus rhamnosus for the manufacture of a composition for reducing, delaying or inhibiting influenza virus replication and for increasing antiviral cytokine(s) in a subject to be or being infected with a respiratory infection. Still, the present invention relates to methods of treating or preventing a respiratory infection in a subject or in an adult subject, intensifying resistance against viruses causing respiratory infections in a subject or in an adult subject, reducing, delaying or inhibiting influenza virus replication in a subject and increasing antiviral cytokine(s) in a subject to be or being infected with a respiratory infection.
Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
* NULIBRY is intended for administration by a healthcare provider. If deemed appropriate by a healthcare provider, NULIBRY may be administered at home by the patient's caregiver. If NULIBRY can be administered by a caregiver/patient, advise them to read the detailed instructions on the preparation, administration, storage, and disposal of NULIBRY for caregivers [see Instructions for Use].
  * NULIBRY is for intravenous infusion only. Administer with non-DEHP tubing with a 0.2 micron filter. Do not mix NULIBRY with other drugs (note NULIBRY is reconstituted with Sterile Water for Injection, USP). Do not administer as an infusion with other drugs. 
  * NULIBRY is given through an infusion pump at a rate of 1.5 mL per minute. 
  * Dose volumes below 2 mL may require syringe administration through slow intravenous push. 
  * Administration of NULIBRY must be completed within 4 hours of reconstitution [see Dosage and Administration (2.5)].
BACKGROUND: Delayed spinal epidural hematoma (SEH) following central neuraxial block (CNB) is a rare but serious complication. The underlying causes of SEH associated with neuraxial anesthesia are still unclear. Furthermore, the decision between surgical intervention and conservative management for SEH remains a complex and unresolved issue.
CASE PRESENTATION: We report a case of delayed SEH in a 73-year-old woman who underwent vaginal hysterectomy under combined spinal-epidural anesthesia, with the administration of postoperative anticoagulants to prevent deep vein thrombosis on the 1st postoperative day (POD). She experienced symptoms 56 h after CNB. Magnetic resonance imaging (MRI) revealed a dorsal SEH at the L1-L4 level with compression of the thecal sac. On conservative treatment, full recovery was achieved after six months.
CONCLUSIONS: This case reminds anesthesiologists should be alert to the possible occurrence of a delayed SEH following CNB, particularly with the administration of anticoagulants. Immediate neurological evaluation of neurological deficit and MRI are advised. Conservative treatment combined with close and dynamic neurological function monitoring may be feasible for patients with mild or nonprogressive symptoms even spontaneous recovery.